Unmet needs in the treatment of glioblastoma

References

• Salcman M. Glioblastoma and malignant astrocytoma. In: Brain Tumors: An Encyclopedic Approach. Kaye AH, Laws ER Jr (Eds). Churchill Livingstone, Edinburgh, UK 449–478 (1995).
   Google Scholar
• Olson JJ, Ryken T. Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J. Neurooncol.89(3), 255–258 (2008).
   PubMedGoogle Scholar
• Wrensch M, Minn Y, Chew T et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro. Oncol.4, 278–299, (2002).
   PubMed Web of Science ®Google Scholar
• Chakrabarti I, Cockburn M, Cozen W et al. A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer104, 2798–2806 (2005).
   PubMed Web of Science ®Google Scholar
• Elia-Pasquet S, Provost D, Jaffre A et al. Incidence of central nervous system tumors in Gironde, France. Neuroepidemiology23, 110–117 (2004).
   PubMedGoogle Scholar
• Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985–1999. Neuro. Oncol.8, 27–37 (2006).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Reiner AS, Panageas KS et al. Patterns of care in elderly glioblastoma patients. Ann. Neurol.64(6), 628–634 (2008).
   PubMed Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med.356(15), 1527–1535 (2007).
   PubMed Web of Science ®Google Scholar
• Idbaih A, Taillibert S, Simon JM et al. Short course of radiation therapy in elderly patients with glioblastoma multiforme. Cancer Radiother.12(8), 788–792 (2008).
   PubMed Web of Science ®Google Scholar
• Minniti G, De Sanctis V, Muni R et al. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J. Neurooncol.91(1), 95–100 (2009).
   PubMed Web of Science ®Google Scholar
• Shaffrey ME, Mut M, Asher AL et al. Brain metastases. Curr. Probl. Surg.41(8), 665–741 (2004).
   PubMedGoogle Scholar
• Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol.114, 97–109 (2007).
   PubMed Web of Science ®Google Scholar
• Campos S, Davey P, Hird A et al. Brain metastasis from an unknown primary, or primary brain tumour? A diagnostic dilemma. Curr. Oncol.16(1), 62–66 (2009).
   PubMedGoogle Scholar
• Schiff D. Single brain metastasis. Curr. Treat. Options Neurol.3, 89–99 (2001).
   PubMedGoogle Scholar
• McMillan KM, Ehtesham M, Stevenson RT et al. T2 detection of tumor invasion within segmented components of glioblastoma multiforme. J. Magn. Reson. Imaging29(2), 251–257 (2009).
   PubMedGoogle Scholar
• Wang S, Kim S, Chawla S et al. Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage44(3), 653–660 (2009).
   PubMedGoogle Scholar
• García-Gómez JM, Luts J, Julià-Sapé M et al. Multiproject-multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy. MAGMA22(1), 5–18 (2009).
   PubMedGoogle Scholar
• Wang W,Steward CE, Desmond PM: Diffusion tensor imaging in glioblastoma multiforme and brain metastases: the role of p, q, l, and fractional anisotropy. AJNR Am. J. Neuroradiol.30, 203–208 (2009).
   PubMedGoogle Scholar
• Brandes AA, Tosoni A, Franceschi E et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J. Clin. Oncol.27(8), 1275–1279 (2009).
   PubMed Web of Science ®Google Scholar
• Preusser M. MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol. Histopathol.24(4), 511–518 (2009).
   PubMedGoogle Scholar
• Murat A, Migliavacca E, Gorlia T et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol.26(18), 3015–3024 (2008).
   PubMed Web of Science ®Google Scholar
• Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg. Neurol.52, 371–379 (1999).
   PubMed Web of Science ®Google Scholar
• Kowalczuk A, Macdonald RL, Amidei C et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery41, 1028–1038 (1997).
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg.95, 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery29, 385–389 (1991).
   PubMed Web of Science ®Google Scholar
• Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J. Neurosurg.73, 331–344 (1990).
   PubMed Web of Science ®Google Scholar
• Metcalfe SE, Grant R: Biopsy versus resection for malignant glioma. Cochrane Database Syst. Rev.3, CD002034 (2005).
   Google Scholar
• Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J. Neurooncol.42, 227–231 (1999).
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Chaichana KL, Gathinji M et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J. Neurosurg.110(1), 156–162 (2009).
   PubMed Web of Science ®Google Scholar
• Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery34, 45–61 (1994).
   PubMed Web of Science ®Google Scholar
• Stummer W, Novotny A, Stepp H et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J. Neurosurg.93(6), 1003–1013 (2000).
   PubMed Web of Science ®Google Scholar
• Siomin V, Barnett G. Intraoperative imaging in glioblastoma resection. Cancer J.9(2), 91–98 (2003).
   PubMedGoogle Scholar
• Stummer W, Pichlmeier U, Meinel T et al. ALA Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre Phase III trial. Lancet Oncol.7, 392–401 (2006).
   PubMed Web of Science ®Google Scholar
• Pichlmeier U, Bink A, Schackert G et al. ALA Glioma Study Group. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro. Oncol.10(6), 1025–1034 (2008).
   PubMed Web of Science ®Google Scholar
• Barbagallo GM, Jenkinson MD, Brodbelt AR. ‘Recurrent’ glioblastoma multiforme, when should we reoperate? Br. J. Neurosurg.22(3), 452–455 (2008).
   PubMed Web of Science ®Google Scholar
• Barker FG, Chang SM, Gutin PH et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery42, 709–720 (1998).
   PubMed Web of Science ®Google Scholar
• Ryken TC, Frankel B, Julien T et al. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. J. Neurooncol.89(3), 271–286 (2008).
   PubMedGoogle Scholar
• Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet345, 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Von Eckardstein KL, Reszka R, Kiwit JC. Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma – clinical observations. J. Neurooncol.74(3), 305–309 (2005).
   PubMedGoogle Scholar
• Stylli SS, Kaye AH, MacGregor L et al. Photodynamic therapy of high grade glioma—long term survival. J. Clin. Neurosci.12, 389–398 (2005).
   PubMedGoogle Scholar
• Kunwar S, Westphal M, Medhorn M et al. Results from precise: a randomized Phase 3 study in patients with first recurrent glioblastoma multiforme (GBM) comparing cintredekin besudotox (RT) administered via convection-enhanced delivery (CED) with gliadel wafers (GW). Presented at: The 12th Annual Meeting of the Society for Neuro-Oncology. Dallas, TX, USA, 15–18 November 2007.
   Google Scholar
• Mut M, Sherman JH, Shaffrey ME et al. Cintredekin besudotox in treatment of malignant glioma. Expert Opin Biol. Ther.8(6), 805–812 (2008).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabani G, Archer GE et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro. Oncol.10(3), 320–329 (2008).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Duma CM, Schiltz PM et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J. Immunother.27, 398–404 (2004).
   PubMed Web of Science ®Google Scholar
• Prados MD, McDermott M, Chang SM et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a Phase I/II multi-institutional trial. J. Neurooncol.65, 269–278 (2003).
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J. Neurosurg.110(3), 583–588 (2009).
   PubMed Web of Science ®Google Scholar
• Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocol. Int. J. Radiat. Oncol. Biol. Phys.60(3), 853–860 (2004).
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Gerson SL, Denis L et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer88, 1004–1011 (2003).
   PubMed Web of Science ®Google Scholar
• Dall’oglio S, D’Amico A, Pioli F et al. Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. J. Neurooncol.90(3), 315–319 (2008).
   PubMedGoogle Scholar
• Glas M, Happold C, Rieger J et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J. Clin. Oncol.27(8), 1257–1261 (2009).
   PubMed Web of Science ®Google Scholar
• Nieder C, Adam M, Molls M et al. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit. Rev. Oncol. Hematol.60(3), 181–193 (2006).
   PubMed Web of Science ®Google Scholar
• Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat. Rev.26, 397–409 (2000).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncol.22(23), 4779–4786 (2004).
   PubMed Web of Science ®Google Scholar
• Fazeny-Dörner B, Veitl M, Wenzel C et al. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs14(6), 437–442 (2003).
   PubMedGoogle Scholar
• Brandes AA, Ermani M, Turazzi S et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a Phase II study. J. Clin. Oncol.17(2), 645–650 (1999).
   PubMed Web of Science ®Google Scholar
• Fabrini MG, Silvano G, Lolli I et al. A multi-institutional Phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J. Neurooncol.92(1), 79–86 (2009).
   PubMed Web of Science ®Google Scholar
• Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2008.10.043 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol.91(3), 329–336 (2009).
   PubMed Web of Science ®Google Scholar
• Martin V, Liu D, Gomez-Manzano C. Encountering and advancing through antiangiogenesis therapy for gliomas. Curr. Pharm. Des.15(4), 353–364 (2009).
   PubMedGoogle Scholar
• Blumenthal DT, Won M, Mehta MP et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J. Clin. Oncol.27(5), 733–739 (2009).
   PubMed Web of Science ®Google Scholar
• Pirzkall A, McGue C, Saraswathy S et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro. Oncol. DOI:10.1215/15228517-2009-005 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer113(2), 405–410 (2008).
   PubMed Web of Science ®Google Scholar
• Gerstner ER, McNamara MB, Norden AD et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J. Neurooncol. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Peca C, Pacelli R, Elefante A et al. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin. Neurol. Neurosurg. DOI: 10.1016/j.clineuro.2008.11.003 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Mason WP, Maestro RD, Eisenstat D et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr. Oncol.14(3), 110–117 (2007).
   PubMedGoogle Scholar
• Siomin V, Angelov L, Li L et al. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J. Neurooncol.74(2), 211–215 (2005).
   PubMed Web of Science ®Google Scholar
• Rosati A, Tomassini A, Pollo B et al. Epilepsy in cerebral glioma: timing of appearance and histological correlations. J. Neurooncol. DOI: 10.1007/s11060-009-9796-5 (2009) (Epub ahead of print).
   Google Scholar
• Sirven JI, Wingerchuk DM, Drazkowski JF et al. Seizure prophylaxis in patients with brain tumors: a metanalysis. Mayo Clin. Proc.79, 1489–1494, (2004).
   PubMed Web of Science ®Google Scholar
• Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol.2, 404–409 (2003).
   PubMed Web of Science ®Google Scholar
• Wick W, Menn O, Meisner C et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie28, 391–396 (2005).
   PubMedGoogle Scholar
• Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J. Neurooncol.78, 99–102 (2006).
   PubMed Web of Science ®Google Scholar
• Saraswathy S, Crawford FW, Lamborn KR et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J. Neurooncol.91(1), 69–81 (2009).
   PubMed Web of Science ®Google Scholar